U.S. policymakers have reportedly told the Health Resources and Services Administration it must continue to work within its current resources to keep the 340B drug discount program in check, according to a Modern Healthcare report.
Despite HRSA Officer of Pharmacy Affairs Director Capt. Krista Pedley’s concerns about the lack of rulemaking authority regarding the program, Republicans and Democrats in the Senate health committee and House Energy and Commerce Committee say the agency may be falling short with its current powers.
“While we appreciate that HRSA has requested these additional authorities, we remain concerned that the agency is not using its existing authorities,” lawmakers said. “We believe HRSA action to issue or implement final regulations in an open and transparent process, in collaboration with all relevant stakeholders, could help clarify and update program requirements in pursuit of strengthening access to necessary care and proper administration of the program.”
Lawmakers asked HRSA to establish protocol for 340B ceiling prices, and added that it can levy a fine against drugmakers that “knowingly and intentionally overcharge a covered entity for a 340B drug.”
To read the full report on Modern Healthcare, click here. (Paid subscription required)